Realizing the full potential of the
plant Cannabis and making it accessible
to patients with the goal of improving their
quality of life

Realizing the full potential of the plant Cannabis and making it accessible to patients with the goal of improving their quality of life

TASE:TKUN

-

About

Tikun Olam was established in 2006 and acquired by Cannbit Pharmaceuticals in 2019. Tikun Olam-Cannbit is Israel’s first and leading supplier of cannabis. A groundbreaker in clinical research, it is renowned worldwide as a pioneer in the field of modern medical cannabis. Since its establishment, Tikun Olam-Cannbit has treated more than 30,000 patients in Israel from childhood through to old age with a variety of illnesses, and has the most experience worldwide in the treatment of patients and in alleviating their suffering through medical cannabis

Innovation throughout the value chain

35 clinical and pre-clinical trials and 19 publications in the world’s leading scientific journals
Genetic R&D

Identical cultivation in changing environmental conditions

Organic cultivation using biological pesticides

INDOOR
2,100 sq.m adapted
to EU-GMP standards
Ready for export

Production capacity of 22 tons of cannabis inflorescences and oils annually

ISO8 Standard for clean rooms, production processes, packaging, and logistics center
ISO17025 Standard

14 different analytical tests

Identification and measurement of more than 28 different plant components
A storage and distribution service system

Pharmacy, regulatory and marketing services
A green pharmacy
in the heart of Tel Aviv
More than 10 years of experience

צA team of certified nurses (male and female)

Counseling and support for patients and their families
Development of products and technologies in collaboration with leading global pharma companies as well as marketing and distribution agreements worldwide

Leading research in the medical cannabis industry

15

years of research

More than

35

clinical studies

Cumulative data on

15,000

Patients

Some

19

articles published in scientific journals

6

Clinical trials in progress

Media

Sign up to Email Alerts